Published On: Wed, Oct 19th, 2016

Upgrades And Downgrades For Merck & Company, Inc. (NYSE:MRK)


Recently stock market analysts have updated their consensus ratings on shares of Merck & Company, Inc. (NYSE:MRK).

Most recent broker ratings

10/13/2016 – Merck & Company, Inc. was upgraded to “buy” by analysts at Bank of America Merrill Lynch. They now have a USD 70 price target on the stock.

10/10/2016 – Merck & Company, Inc. had its “overweight” rating reiterated by analysts at Barclays.

10/10/2016 – Merck & Company, Inc. had its “market perform” rating reiterated by analysts at Leerink Swann. They now have a USD 65 price target on the stock.

09/13/2016 – Merck & Company, Inc. had its “buy” rating reiterated by analysts at Argus. They now have a USD 65 price target on the stock.

09/12/2016 – Merck & Company, Inc. had its “hold” rating reiterated by analysts at Jefferies. They now have a USD 56 price target on the stock.

09/06/2016 – Merck & Company, Inc. had its “buy” rating reiterated by analysts at UBS.

08/09/2016 – Merck & Company, Inc. had its “outperform” rating reiterated by analysts at Sanford C. Bernstein. They now have a USD 74 price target on the stock.

08/08/2016 – Merck & Company, Inc. had its “hold” rating reiterated by analysts at Deutsche Bank. They now have a USD 59 price target on the stock.

08/08/2016 – Merck & Company, Inc. had its “neutral” rating reiterated by analysts at Citigroup. They now have a USD 65 price target on the stock.

08/08/2016 – Merck & Company, Inc. had its “neutral” rating reiterated by analysts at Piper Jaffray. They now have a USD 62 price target on the stock.

08/08/2016 – Merck & Company, Inc. was upgraded to “outperform” by analysts at Credit Suisse. They now have a USD 73 price target on the stock.

08/05/2016 – Merck & Company, Inc. was upgraded to “outperform” by analysts at BMO Capital Markets. They now have a USD 72 price target on the stock.

06/07/2016 – Merck & Company, Inc. had its “neutral” rating reiterated by analysts at Goldman Sachs. They now have a USD 60 price target on the stock.

05/19/2016 – Merck & Company, Inc. had its “overweight” rating reiterated by analysts at JP Morgan.

04/06/2016 – Societe Generale began new coverage on Merck & Company, Inc. giving the company a “buy” rating. They now have a USD 80 price target on the stock.

Merck & Company, Inc. has a 50 day moving average of 62.50 and a 200 day moving average of 58.90. The stock’s market capitalization is 171.69B, it has a 52-week low of 47.97 and a 52-week high of 64.86.

The share price of the company (NYSE:MRK) was up +0.93% during the last trading session, with a high of 62.62 and the volume of Merck & Company, Inc. shares traded was 9987994.

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Company’s animal health products are sold to veterinarians, distributors and animal producers.